ImmunityBio Reports 100% Disease Control Rate in Recurrent Glioblastoma with Novel Combination Therapy; Novo Nordisk Enters $550M Self-Replicating RNA Collaboration with Replicate Bioscience

100%Disease Control Rate! Positive Trial Results of Potential Blockbuster Therapy Combination Announced

ImmunityBio recently announced the latest results of an exploratory study. The study evaluates its immune enhancement regimen for treatment.Efficacy and Safety in 5 Patients with Recurrent Glioblastoma (GBM). The solutionIncludingIL-15 AgonistAnktiva（nogapendekin alfa inbakicept，Aimed at enhancing natural killer cell activity）, NK cell therapy (PD-L1 t-haNK), and the Optune Gio tumor electric field treatment device. Analysis shows,Among the five patients receiving treatment, three achieved remission, with two nearing complete remission, and the other two maintaining stable disease to date. The overall disease control rate (DCR) of the patients reached 100%.The press release pointed out,For recurrent GBM second-line patients, the positive trial results of this chemotherapy-free regimen are highly significant. Based on these preliminary findings, ImmunityBio plans to initiate a randomized controlled clinical trial specifically targeting second-line GBM patients who experience disease recurrence after standard treatment.

Novo Nordisk Reaches $550 Million RNA Therapy Collaboration

Replicate Bioscience Announces Multi-Year Research Collaboration with Novo NordiskThis collaboration will combine Novo Nordisk's extensive experience in treatment and drug development with Replicate Bioscience's innovative self-replicating RNA (srRNA) platform to jointly develop novel candidate therapies for the treatment of obesity, type 2 diabetes, and other cardiometabolic diseases.According to the agreement, the two parties will cooperate on specific cardiometabolic disease targets, and Novo Nordisk will obtain a global exclusive license for the Replicate srRNA platform to develop and commercialize related projects.Replicate Bioscience to Receive Research Funding and Be Eligible for Up to $550 Million in Financial Support from Novo Nordisk, including upfront and potential milestone payments.

Replicate Bioscience possesses a comprehensive proprietary srRNA technology capable of customizing protein expression profiles based on specific needs. Compared to other RNA technologies, its platform demonstrates higher levels of protein expression in vivo, longer-lasting effects, and more flexible regulation capabilities. Replicate Bioscience is addressing the limitations of traditional RNA therapies through its innovative srRNA technology, showing potential improvements in bioactivity, immune response intensity, and therapeutic index. Currently, the company’s clinical-stage rabies vaccine, RBI-4000, has shown protective immunity at dose levels lower than other RNA vaccines in Phase 1 trials.

References:

[1] Replicate Bioscience Announces Partnership with Novo Nordisk to Unlock Self-Replicating RNA Therapies for Obesity and Diabetes. Retrieved August 28, 2025 from https://www.prnewswire.com/news-releases/replicate-bioscience-announces-partnership-with-novo-nordisk-to-unlock-self-replicating-rna-therapies-for-obesity-and-diabetes-302540245.html

[2] Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device. Retrieved August 28, 2025 from https://www.businesswire.com/news/home/20250826147574/en/Initial-Data-Shows-100-Disease-Control-in-5-Out-of-5-Patients-With-Recurrent-Glioblastoma-With-Two-Patients-in-Near-Complete-Response-Treated-With-ImmunityBios-ANKTIVA-NK-Cell-Therapy-Plus-Optune-Gio-Device